Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614726 · ClinicalTrials.gov registry record · NA
A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study
A NA study of Constipation and Microbiota, sponsored by The Center for Applied Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05614726: Completed NA study of Constipation and Microbiota, sponsored by The Center for Applied Health Sciences.
NCT05614726 is a NA study of Constipation and Microbiota that has completed, run by The Center for Applied Health Sciences. The registered enrollment target is 52 participants, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05614726, a NA study of Constipation and Microbiota, has completed, sponsored by The Center for Applied Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e., The Center for Applied Health Sciences). Subjects will attend three study visits. During Visit 1, subjects will be screened for participation \[i.e., medical history, routine blood work, background baseline diet\]. During Visits 2 and 3 subjects will complete questionnaires that assess their gastrointestinal health (e.g., abdominal discomfort/bloating, constipation, regularity, stool consistency). Visits 2 and 3 will correspond to before (week 0) and after six weeks of supplementation, respectively, with the probiotic dietary supplement or placebo.
Primary Outcome
Flatulence (gas) as measured by a 10 cm visual analogue scale, where higher values represent greater flatulence.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Study Locations (1)
Ohio
- The Center for Applied Health Sciences - Canfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2022-03-17 |
| Phase | NA |
What the finished NCT05614726 record still lists
NCT05614726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase is the first listed.
NCT05614726 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05614726 about?
NCT05614726 is a clinical study titled "A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study". This randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e., The Center for Applied Health Sciences). Subjects will atten...
What is the current status of trial NCT05614726?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2021-06-18. Estimated completion is 2022-03-17.
What conditions does trial NCT05614726 study?
This clinical trial studies the following conditions: Constipation, Microbiota, Candida.
What interventions are being tested in trial NCT05614726?
The interventions under investigation include: 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05614726?
This trial is sponsored by The Center for Applied Health Sciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05614726 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05614726's enrollment target sits among peer trials
52 32nd of 54 higher than 22 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Management of Dyssynergic Defecation
RECRUITING · NA
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
RECRUITING · NA
-
Understanding Mechanisms of Normal and Disordered Defecation
RECRUITING · NA
-
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI